我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

冠状动脉再狭窄的防治研究(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2000年第3期
页码:
221-223
栏目:
综述
出版日期:
2000-05-25

文章信息/Info

Title:
-
作者:
王睿1;  高歌2
第四军医大学:1 学报编辑部; 2 西京医院心脏内科，陕西 西安 710032
Author(s):
-
关键词:
术后再狭窄; 冠状动脉; 经皮腔内冠状动脉成形术; 支架; 防治
Keywords:
-
分类号:
R972；R654
DOI:
-
文献标识码:
A
摘要:
作者从血小板功能抑制剂、抗凝血药、溶血栓药、血管平滑肌细胞增殖抑制剂、物理治疗等方面综述了PTCA 支架后冠脉再狭窄的防治研究进展。
Abstract:
-

参考文献/References

［1］ Cecena FA. Stenting stent: alternative strategy for treating in-stent restenosis［J］. Cathet Cardiovasc Diagn, 1996, 39(4): 377.

［2］ Le-Feuvre C, Tahlil O, Feldman LJ et al. Prospects of prevention of restenosis after coronary angioplasty［J］. Ann Cardiol Angeiol Paris, 1996, 45(7): 383.

［3］ Goods CM, al-Shaibi KF, Liu MW. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting［J］. Am J Cardiol, 1996, 78(9): 1042.

［4］ Barragan P, Pietri P, Villain P et al. Antiplatelet therapy during coronary endoprosthesis placement［J］. Arch Mal Coeur Vaise, 1996, 89(11 Suppl) : 1515.

［5］ Gregorini L, Marco J. Ticlopidine and aspirin interactions［J］. Heart, 1997, 77(1): 11.

［6］ Fidder GI, Lumley P. Preliminary clinical syudies with thromboxane synthase inhibitors and thromboxane receptors blockers［J］. Circulation, 1990, 81:69.

［7］ 郭　丽，郑　虎. 国外正在研制的血小板药物［J］. 中国药学杂志, 1995,30：628.

［8］ Jang IKK, Fuster V. Cardiovascular pharmacology and therapeutics［M］. New York: Churchill Livingstone Press, 1994:551.

［9］ Sheth SB, Colman RW. Platelet cAMP and cGMP phosphodiesterases［J］. Platelet, 1994, 5:61.

［10］ Tcheng JE. Outcome of patients treated with the GP IIb/IIIa inhibitor integrelin during coronary angioplasty: results of the IMPACT study［J］. Circulation, 1993, 88(11 suppl):501

［11］ Tcheng JE, Harrington RA, Kottke-Marchant K. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet intergrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators［J］. Circulation, 1995, 91(8): 2151.

［12］ Schuiki E, Fcchini M, Amann FW. Anti-thrombosis therapy following coronary stent implantation［J］. Schweiz Rundsch Med Prax, 1996, 85(42): 1316.

［13］ Hardhammar PA, van-Beusekom HM, Emanuelsson HU, et al. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries［J］. Circulation, 1996，93(3): 423.

［14］ Spinler S, Cheng J. Antithrombotic therapy after intracoronary stenting［J］. Pharmacotherapy, 1997, 17(1): 74.

［15］ Markward F. Development of hirudin as an antithrombotic agent［J］. Semin Throm Hemost, 1989, 15: 269.

［16］ Hirsh J. Optimal intensity and monitoring warfarin［J］. Am J Cardiol, 1995, 75: 39.

［17］ 肖红雨，周万松. 磁场生物效应的国内进展［J］. 中华理疗杂志，1999,22（1）：49.

［18］ Waksman R. Local catheter-based intracoronary radiation therapy for restenosis［J］. Am J Cardiol, 1996, 78(3A): 23.

［19］ Kurbaan AS, Kelly PA, Sigwart U. Cutting balloon angioplasty and stenting for aorto-ostial lesions［J］. Heart, 1997, 77(4): 350.

［20］ Van-Beusekom HM, Serruys PW, van-der-Giessen WJ. Coronary stent coatings［J］. Coron Artery Dis, 1994, 5(7): 590.

备注/Memo

备注/Memo:
收稿日期：1999-11-17.
更新日期/Last Update: 2000-05-25